- Home
- Companies
- Pishtaz Teb Zaman Diagnostics
- Products
- Pishtaz - Model PT-CEA-96 - Tumor ...
Pishtaz - Model PT-CEA-96 - Tumor Marker Elisa Kit
Carcinoembroyonic antigen (CEA) is a 150300 kD glycoprotein molecule which has been found by Gold and Freedman at 1965 and it is also known as major component of CEA glycoprotein family. This family consists of 36 different glycoproteins with the common feature of close similarity of their structural domain to IgG heavy chain structure. Carbohydrate constitutes 45-55% of the CEA whole molecule and its polypeptide chain formed by 641 aminoacids.
- 75 min Total Time
- Antigen Capture Assay Type
- 96 Tests Package Size
- 0.2 ng/ml Minimum Detection
During the fetal period and prior to birth, endothelial cells and after birth epithelial cells are mainly contributed to CEA production and secretion. It is also shown that adenocarcinoma cells of the colon and fetal intestinal cells produce CEA during their life period. Several factors affect CEA serum level including CEA gene expression in source tissue, its synthesis and secretion level, CEA half life in circulation, tumor necrosis and vascularization level and finally its catabolism in liver. Normal level in healthy nonsmoker individuals is about 2.5-5 ng/ml (95-98% of healthy people are under 5 ng/ml) but in smoker individuals, eleveated levels (5-10 ng/ml) have been reported. It is also shown that males CEA level is more than females and olds individuals have higher level than youths. Elevated levels of CEA are found in many cancers. More than 80% of patients with advanced adenocarcinoma of the colon and more than 30% of patients with cancer of the lung, liver, pancreas, breast, head or neck, bladder, cervix, and prostate have been showed to have increased levels of CEA. However, CEA assay per se should not used as final cancer diagnostic test since its increase is also reported in various benign conditions. Chronic liver disease (90%), acute liver disease (50%), liver cirrohsis (45%), pulmonary emphysema (30%), intestinal polyps (5%) and ulcerative colitis (15%) are benign conditions which were reported with high CEA level . However in all benign conditions CEA level is not more than 10 ng/ml. Elevated plasma levels are related to the stage and extent of the disease, the degree of differentiation of the tumor, and the site of metastasis. Normally the CEA assay can be used for the diagnosis of colon adenocarcinoma cancer stage, treatment followup and prognosis of the disease but not as screening test. The CEA Quantitative Enzyme Immunoassay provides a rapid, sensitive, and reliable assay for CEA level.
Factor : Value
- Assay Type : Antigen Capture (Antibody Sandwich)
- Chromogen Substrate : Ready to Use
- Conjugate : Ready to Use
- Control : Two Vials: Negative and Positive
- Incubation time : (Room Temperature) 30 + 30 + 15 min
- Standards : ng/ml 0 , 2 , 5 , 20 , 50 , 100
- Required Samplers : μl 50 , 100